Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 136

Similar articles for PubMed (Select 16352804)

1.

Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.

Serrano LM, Pfeiffer T, Olivares S, Numbenjapon T, Bennitt J, Kim D, Smith D, McNamara G, Al-Kadhimi Z, Rosenthal J, Forman SJ, Jensen MC, Cooper LJ.

Blood. 2006 Apr 1;107(7):2643-52. Epub 2005 Dec 13.

2.

IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.

Pegram HJ, Purdon TJ, van Leeuwen DG, Curran KJ, Giralt SA, Barker JN, Brentjens RJ.

Leukemia. 2015 Feb;29(2):415-22. doi: 10.1038/leu.2014.215. Epub 2014 Jul 9.

PMID:
25005243
3.

T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.

Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A, Wright C, Popplewell L, Raubitschek A, Forman SJ, Jensen MC.

Blood. 2003 Feb 15;101(4):1637-44. Epub 2002 Oct 10.

4.

Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy.

Marin V, Dander E, Biagi E, Introna M, Fazio G, Biondi A, D'Amico G.

Exp Hematol. 2006 Sep;34(9):1219-29.

PMID:
16939815
5.

Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.

Cooper LJ, Ausubel L, Gutierrez M, Stephan S, Shakeley R, Olivares S, Serrano LM, Burton L, Jensen MC, Forman SJ, DiGiusto DL.

Cytotherapy. 2006;8(2):105-17.

PMID:
16698684
7.

Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.

Davies JK, Singh H, Huls H, Yuk D, Lee DA, Kebriaei P, Champlin RE, Nadler LM, Guinan EC, Cooper LJ.

Cancer Res. 2010 May 15;70(10):3915-24. doi: 10.1158/0008-5472.CAN-09-3845. Epub 2010 Apr 27.

8.

Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.

Cooper LJ, Al-Kadhimi Z, DiGiusto D, Kalos M, Colcher D, Raubitschek A, Forman SJ, Jensen MC.

Blood Cells Mol Dis. 2004 Jul-Aug;33(1):83-9. Review.

PMID:
15223016
9.

In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy.

Lee JC, Hayman E, Pegram HJ, Santos E, Heller G, Sadelain M, Brentjens R.

Cancer Res. 2011 Apr 15;71(8):2871-81. doi: 10.1158/0008-5472.CAN-10-0552. Epub 2011 Apr 12.

10.

Adoptive cellular immunotherapy with CD19-specific T cells.

Rössig C, Pscherer S, Landmeier S, Altvater B, Jürgens H, Vormoor J.

Klin Padiatr. 2005 Nov-Dec;217(6):351-6.

PMID:
16307422
11.

Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells.

Numbenjapon T, Serrano LM, Chang WC, Forman SJ, Jensen MC, Cooper LJ.

Exp Hematol. 2007 Jul;35(7):1083-90.

PMID:
17588477
12.

Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.

Singh H, Serrano LM, Pfeiffer T, Olivares S, McNamara G, Smith DD, Al-Kadhimi Z, Forman SJ, Gillies SD, Jensen MC, Colcher D, Raubitschek A, Cooper LJ.

Cancer Res. 2007 Mar 15;67(6):2872-80.

13.

Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.

Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, Mi T, Maiti S, Kebriaei P, Lee DA, Champlin RE, Cooper LJ.

Cancer Res. 2011 May 15;71(10):3516-27. doi: 10.1158/0008-5472.CAN-10-3843. Epub 2011 May 10. Erratum in: Cancer Res. 2011 Jul 1;71(13):4734.

14.

Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood.

Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, Shpall EJ, Champlin RE, Singh H, Cooper LJ.

J Vis Exp. 2013 Feb 1;(72):e50070. doi: 10.3791/50070.

15.

A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.

Gidlöf C, Dohlsten M, Lando P, Kalland T, Sundström C, Tötterman TH.

Blood. 1997 Mar 15;89(6):2089-97.

16.

Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.

Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, Hackett PB, Kohn DB, Shpall EJ, Champlin RE, Cooper LJ.

Cancer Res. 2008 Apr 15;68(8):2961-71. doi: 10.1158/0008-5472.CAN-07-5600.

17.

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.

Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, Huls H, Miller JC, Kebriaei P, Rabinovitch B, Lee DA, Champlin RE, Bonini C, Naldini L, Rebar EJ, Gregory PD, Holmes MC, Cooper LJ.

Blood. 2012 Jun 14;119(24):5697-705. doi: 10.1182/blood-2012-01-405365. Epub 2012 Apr 24.

18.

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA.

Blood. 2010 Nov 18;116(20):4099-102. doi: 10.1182/blood-2010-04-281931. Epub 2010 Jul 28.

19.

Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.

Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, Maiti S, Manuri P, Senyukov V, Jena B, Kebriaei P, Champlin RE, Huls H, Cooper LJ.

PLoS One. 2013 May 31;8(5):e64138. doi: 10.1371/journal.pone.0064138. Print 2013.

20.

CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJ.

Cancer Res. 2006 Nov 15;66(22):10995-1004.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk